CU23896B1 - Método para inhibir la replicación del vih en células de mamíferos - Google Patents

Método para inhibir la replicación del vih en células de mamíferos

Info

Publication number
CU23896B1
CU23896B1 CU2010000056A CU20100056A CU23896B1 CU 23896 B1 CU23896 B1 CU 23896B1 CU 2010000056 A CU2010000056 A CU 2010000056A CU 20100056 A CU20100056 A CU 20100056A CU 23896 B1 CU23896 B1 CU 23896B1
Authority
CU
Cuba
Prior art keywords
cytoskeleton
replication
proteins
hiv
inhibiting
Prior art date
Application number
CU2010000056A
Other languages
English (en)
Other versions
CU20100056A7 (es
Inventor
Ortega Celia Berta Fernández
SUÁREZ Anna Caridys RAMÍREZ
Casanova Dionne Casillas
Guerrero Taimi Emelia Paneque
Gómez Raimundo Ubieta
ECHEVARRÍA Marta DUBED
Leyva Leonor Margarita Navea
Serra Lila Rosa Castellanos
Cano Carlos Antonio Duarte
CAMA Viviana FALCÓN
Acosta Osvaldo Reyes
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU2010000056A priority Critical patent/CU23896B1/es
Priority to ARP110101094A priority patent/AR080818A1/es
Priority to US13/637,845 priority patent/US9205128B2/en
Priority to PCT/CU2011/000001 priority patent/WO2011120474A1/es
Priority to KR1020127028726A priority patent/KR101869917B1/ko
Priority to JP2013501620A priority patent/JP5925759B2/ja
Priority to BR112012025092-2A priority patent/BR112012025092B1/pt
Priority to CN201180023063.3A priority patent/CN102884075B/zh
Priority to EP11720370.3A priority patent/EP2554550B1/en
Priority to RU2012146542/10A priority patent/RU2593948C2/ru
Priority to ES11720370.3T priority patent/ES2604702T3/es
Priority to MX2012011424A priority patent/MX2012011424A/es
Priority to CA2794930A priority patent/CA2794930C/en
Priority to MYPI2012700711A priority patent/MY161923A/en
Priority to AU2011235369A priority patent/AU2011235369B2/en
Publication of CU20100056A7 publication Critical patent/CU20100056A7/es
Priority to ZA2012/07761A priority patent/ZA201207761B/en
Publication of CU23896B1 publication Critical patent/CU23896B1/es
Priority to US14/943,096 priority patent/US20160106810A1/en
Priority to US14/943,106 priority patent/US10434137B2/en
Priority to US14/943,089 priority patent/US20160129073A1/en
Priority to JP2016019305A priority patent/JP6230635B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invención describe un método para inhibir la replicación del virus de la inmunodeficiencia humana (VIH) mediante la modulación negativa o alteración del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervención sobre la estructura de estas proteínas causa una inhibición de la replicación del virus en células humanas. La invención se relaciona además con el uso de agentes, que comprenden péptidos y/o ARN de interferentes y/o compuestos lipídicos, y producen la modulación negativa o alteración del citoesqueleto celular, para prevenir o tratar la infección por el VIH. La invención proporciona medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infección por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto.
CU2010000056A 2010-04-01 2010-04-01 Método para inhibir la replicación del vih en células de mamíferos CU23896B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CU2010000056A CU23896B1 (es) 2010-04-01 2010-04-01 Método para inhibir la replicación del vih en células de mamíferos
ARP110101094A AR080818A1 (es) 2010-04-01 2011-03-31 Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos
RU2012146542/10A RU2593948C2 (ru) 2010-04-01 2011-04-01 Способ ингибирования репликации вич в клетках млекопитающих и у людей
MX2012011424A MX2012011424A (es) 2010-04-01 2011-04-01 Metodo para inhibir la repilacion del virus de la inmunodeficiencia humana en celulas de mamiferos y en humanos.
KR1020127028726A KR101869917B1 (ko) 2010-04-01 2011-04-01 포유류와 인간 세포에서 ｈｉｖ 복제를 억제하는 방법
JP2013501620A JP5925759B2 (ja) 2010-04-01 2011-04-01 哺乳動物及びヒトの細胞においてｈｉｖ複製を阻害する方法
BR112012025092-2A BR112012025092B1 (pt) 2010-04-01 2011-04-01 Uso de um peptídeo capaz de romper os filamentos intermediários do citoesqueleto em uma célula de mamífero
CN201180023063.3A CN102884075B (zh) 2010-04-01 2011-04-01 用于抑制在哺乳动物细胞中和在人中的hiv复制的方法
EP11720370.3A EP2554550B1 (en) 2010-04-01 2011-04-01 Method for inhibiting hiv replication in mammal and human cells
US13/637,845 US9205128B2 (en) 2010-04-01 2011-04-01 Method for inhibiting HIV replication in mammal and human cells
ES11720370.3T ES2604702T3 (es) 2010-04-01 2011-04-01 Método para inhibir la replicación del VIH en células de mamíferos y humanos
PCT/CU2011/000001 WO2011120474A1 (es) 2010-04-01 2011-04-01 Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos
CA2794930A CA2794930C (en) 2010-04-01 2011-04-01 Method for inhibiting hiv replication in mammal and human cells
MYPI2012700711A MY161923A (en) 2010-04-01 2011-04-01 Method to inhibit hiv replication in mammal and human cells
AU2011235369A AU2011235369B2 (en) 2010-04-01 2011-04-01 Method for inhibiting HIV replication in mammal and human cells
ZA2012/07761A ZA201207761B (en) 2010-04-01 2012-10-16 Method for inhibiting hiv replication in mammal and human cells
US14/943,096 US20160106810A1 (en) 2010-04-01 2015-11-17 Method for Inhibiting HIV Replication in Mammal and Human Cells
US14/943,106 US10434137B2 (en) 2010-04-01 2015-11-17 Method for inhibiting HIV replication in mammal and human cells
US14/943,089 US20160129073A1 (en) 2010-04-01 2015-11-17 Method for Inhibiting HIV Replication in Mammal and Human Cells
JP2016019305A JP6230635B2 (ja) 2010-04-01 2016-02-03 哺乳動物及びヒトの細胞においてｈｉｖ複製を阻害する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000056A CU23896B1 (es) 2010-04-01 2010-04-01 Método para inhibir la replicación del vih en células de mamíferos

Publications (2)

Publication Number Publication Date
CU20100056A7 CU20100056A7 (es) 2012-06-21
CU23896B1 true CU23896B1 (es) 2013-05-31

Family

ID=44168763

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000056A CU23896B1 (es) 2010-04-01 2010-04-01 Método para inhibir la replicación del vih en células de mamíferos

Country Status (16)

Country Link
US (4) US9205128B2 (es)
EP (1) EP2554550B1 (es)
JP (2) JP5925759B2 (es)
KR (1) KR101869917B1 (es)
CN (1) CN102884075B (es)
AR (1) AR080818A1 (es)
AU (1) AU2011235369B2 (es)
BR (1) BR112012025092B1 (es)
CA (1) CA2794930C (es)
CU (1) CU23896B1 (es)
ES (1) ES2604702T3 (es)
MX (1) MX2012011424A (es)
MY (1) MY161923A (es)
RU (1) RU2593948C2 (es)
WO (1) WO2011120474A1 (es)
ZA (1) ZA201207761B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102131041B1 (ko) 2013-12-03 2020-07-08 (주)아모레퍼시픽 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법
US9885021B2 (en) 2014-06-12 2018-02-06 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
WO2016199964A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
CU20200110A7 (es) * 2020-12-23 2022-08-09 Ct Ingenieria Genetica Biotecnologia Péptidos para el tratamiento de infecciones respiratorias de origen viral
CN115902241B (zh) * 2022-12-01 2025-04-29 中山大学 波形蛋白在制备广州管圆线虫病治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
EP0951544A2 (en) 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6476193B1 (en) * 1998-10-06 2002-11-05 Curagen Corporation NLK1 protein and NLK1 protein complexes
IL148225A0 (en) * 1999-09-01 2002-09-12 Subsidiary No 3 Inc Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR100607611B1 (ko) * 2000-08-24 2006-08-02 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
AU2003224725A1 (en) * 2002-03-20 2003-10-08 Brigham And Women's Hospital, Inc. Hiv therapeutic
US7691582B2 (en) * 2002-09-27 2010-04-06 The Regents Of The University Of Michigan Methods of secretory vimentin detection and modulation
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2599525C (en) * 2005-03-08 2015-05-26 Molmed Spa Hiv vif
US20090227518A1 (en) * 2005-12-02 2009-09-10 The Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Also Published As

Publication number Publication date
CA2794930C (en) 2019-05-21
CA2794930A1 (en) 2011-10-06
WO2011120474A8 (es) 2012-11-15
JP6230635B2 (ja) 2017-11-15
WO2011120474A1 (es) 2011-10-06
KR20130027016A (ko) 2013-03-14
EP2554550A1 (en) 2013-02-06
BR112012025092A2 (pt) 2017-01-10
JP2013523662A (ja) 2013-06-17
JP5925759B2 (ja) 2016-05-25
KR101869917B1 (ko) 2018-06-21
BR112012025092B1 (pt) 2022-03-22
US20160108404A1 (en) 2016-04-21
RU2012146542A (ru) 2014-05-10
US20160106810A1 (en) 2016-04-21
US20160129073A1 (en) 2016-05-12
MY161923A (en) 2017-05-15
CN102884075B (zh) 2018-09-11
JP2016121172A (ja) 2016-07-07
EP2554550B1 (en) 2016-09-07
ES2604702T3 (es) 2017-03-08
AU2011235369B2 (en) 2015-12-24
US10434137B2 (en) 2019-10-08
US20130130971A1 (en) 2013-05-23
AU2011235369A1 (en) 2012-11-01
US9205128B2 (en) 2015-12-08
CN102884075A (zh) 2013-01-16
CU20100056A7 (es) 2012-06-21
AR080818A1 (es) 2012-05-09
MX2012011424A (es) 2012-11-06
RU2593948C2 (ru) 2016-08-10
WO2011120474A9 (es) 2012-03-22
ZA201207761B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
CU23896B1 (es) Método para inhibir la replicación del vih en células de mamíferos
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
UY32539A (es) Artículo cementicio y método para prepararlo
BR112015018493A2 (pt) Linhagens celulares para produção de vírus e métodos de uso
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
BR112017009220A2 (pt) métodos para transdução e processamento de célula
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CU20170118A7 (es) Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
CL2020002089A1 (es) Prevenir o reducir el crecimiento de las plantas por biocementación.
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
MX373660B (es) Fibroblastos de embrion de pollo inmortalizados.
AR089393A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
MX2018006373A (es) Produccion de virus en cultivos celulares.
CL2017002729A1 (es) Proteína de unión a rgma y su uso
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS
BR112017002081A2 (pt) elemento de superfície de controle para uma aeronave
PE20131401A1 (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo
MX2016006551A (es) Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
AR095905A1 (es) Proceso para el entrecruzamiento de elastómeros
MX366836B (es) Celulas aviares para la produccion mejorada de virus.
AR099024A1 (es) Expresión específica de tejido y producción de planta híbrida
CL2018000076A1 (es) Mejora del metabolismo de las microalgas de xilosa.
MX2021008091A (es) Composicion que comprende artropodos y huevos de acaros astigmatidos.
BR112012013352A8 (pt) helicóptero

Legal Events

Date Code Title Description
FG Grant of patent